Literature DB >> 21864741

Insulin pump therapy in adults.

Triantafillos Didangelos1, Fotios Iliadis.   

Abstract

Restoration of the physiological insulin secretion is a current medical challenge and a dream for patients with Diabetes Mellitus. Continuous insulin therapy using pumps was the first step to the development of artificial pancreas. The aim of diabetes treatment is to achieve strict glycemic control in order to avoid the development of long-term diabetic complications while reducing the frequency of hypoglycemic episodes. Continuous subcutaneous insulin infusion (CSII) using an external pump, offers both a better blood glucose stability as compared to multiple daily injections and a broader flexibility in life mode, and reduces the frequency of severe hypoglycemia. The advantages of the insulin pump (consistency of basal delivery, adjustable basal rates, and low insulin depots allowing the reduction of glycemic variability) have contributed to its reported superiority compared with multiple daily injections (MDI). However, experience with CSII indicates that candidates for insulin pump therapy must be carefully selected and strongly motivated to improve their glucose control. Finally, the use of CSII in patients with Diabetes Mellitus type 2 now appears to be a good alternative to the ineffective MDI regimens observed in some of these patients.
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21864741     DOI: 10.1016/S0168-8227(11)70025-0

Source DB:  PubMed          Journal:  Diabetes Res Clin Pract        ISSN: 0168-8227            Impact factor:   5.602


  8 in total

1.  Reductions in A1C with pump therapy in type 2 diabetes are independent of C-peptide and anti-glutamic acid decarboxylase antibody concentrations.

Authors:  Yves Reznik; Suiying Huang
Journal:  Diabetes Technol Ther       Date:  2014-09-05       Impact factor: 6.118

2.  Glycemic Variability Is Associated with Frequency of Blood Glucose Testing and Bolus: Post Hoc Analysis Results from the ProAct Study.

Authors:  Andreas Pfützner; Jörg Weissmann; Stavroula Mougiakakou; Elena Daskalaki; Norbert Weis; Ralph Ziegler
Journal:  Diabetes Technol Ther       Date:  2015-03-03       Impact factor: 6.118

Review 3.  Treating type 1 diabetes: from strategies for insulin delivery to dual hormonal control.

Authors:  A L McCall; L S Farhy
Journal:  Minerva Endocrinol       Date:  2013-06       Impact factor: 2.184

4.  Model-based sensor-augmented pump therapy.

Authors:  Benyamin Grosman; Gayane Voskanyan; Mikhail Loutseiko; Anirban Roy; Aloke Mehta; Natalie Kurtz; Neha Parikh; Francine R Kaufman; John J Mastrototaro; Barry Keenan
Journal:  J Diabetes Sci Technol       Date:  2013-03-01

5.  Opinions and Satisfaction Regarding Continuous Subcutaneous Insulin Infusion Therapy in Adult Patients with Type 1 Diabetes.

Authors:  Ikuko Nishio; Masami Chujo; Tsuyoshi Ohkura; Hideyuki Kataoka
Journal:  Yonago Acta Med       Date:  2015-10-14       Impact factor: 1.641

Review 6.  Membranes to achieve immunoprotection of transplanted islets.

Authors:  Julien Schweicher; Crystal Nyitray; Tejal A Desai
Journal:  Front Biosci (Landmark Ed)       Date:  2014-01-01

7.  A qualitative study exploring patients' experiences regarding insulin pump use.

Authors:  Zahra Khalil Alsairafi; Felicity J Smith; Kevin Michael Geoffrey Taylor; Fatemah Alsaleh; Abdulnabi T Alattar
Journal:  Saudi Pharm J       Date:  2018-02-06       Impact factor: 4.330

8.  Impact of insulin pump on quality of life of diabetic patients.

Authors:  Haider Ghazanfar; Syed Wajih Rizvi; Aliya Khurram; Fizza Orooj; Iman Qaiser
Journal:  Indian J Endocrinol Metab       Date:  2016 Jul-Aug
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.